Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2+ and decreased levels of IL23R+ CD4+ T - Lymphocytes in multiple sclerosis

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Kress Bennett, Jennifer M ^a   Ehrlich, Garth D ^a,b   Bruno, Ashley ^c   Post, J Christopher ^a,b   Hu, Fen Z ^a,b   Scott, Thomas F ^b,c  

^a ALLEGHENY SINGER RESEARCH INSTITUTE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 23 RECEPTOR; MESSENGER RNA; STAT4 PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DENSITOMETRY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN PHOSPHORYLATION; UPREGULATION; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ADULT; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GENE EXPRESSION; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; INTERLEUKIN-12 RECEPTOR BETA 2 SUBUNIT; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-12;

EID: 83655203230     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-155     Document Type: Article

References (12)

1. Arnason BG. Immunologic therapy of multiple sclerosis. Annu Rev Med 1999, 50:291-302. 10.1146/annurev.med.50.1.291, 10073279.
2. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747. 10.1146/annurev.immunol.23.021704.115707, 15771584.
3. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F. T-Helper 17 Cells Expand in Multiple Sclerosis and Are Inhibited by Interferon-β. Ann Neurol 2009, 65:499-509. 10.1002/ana.21652, 19475668.
4. Alexander JS, Harris MK, Wells SR, Mills G, Chalamidas K, Ganta VC, McGee J, Jennings MH, Gonzales-Toledo E, Minagar A. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-β1b. Mult Scler 2010, 16:801-809. 10.1177/1352458510370791, 20621951.
5. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007, 8:345-350.
6. Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, Ehrlich GD. Gene expression changes in peripheral blood mononuclear cells from Multiple Sclerosis patients undergoing β-Interferon therapy. J Neurol Sci 2007, 258:52-59. 10.1016/j.jns.2007.02.034, 17467740.
7. Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F. Increased IL-10 mRNA and IL-23 m RNA expression in multiple sclerosis: interferon-{beta} treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler 2008, 14:622-630. 10.1177/1352458507087136, 18424480.
8. Martin-Saavedra FM, Gonzalez-Garcia C, Bravo B, Ballester S. β interferon restricts the inflammatory potential of CD4+ cells through the boost of the TH17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol 2008, 45:4008-4019. 10.1016/j.molimm.2008.06.006, 18639934.
9. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C. T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010, 16:406-412. 10.1038/nm.2110, 3042885, 20348925.
10. Wandinger KP, Stürzebecher CS, Bielekova B, Detore G, Rosenwald A, Staudt LM, McFarland HF, Martin R. Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 2001, 50:349-357. 10.1002/ana.1096, 11558791.
11. Zhang X, Markovic-Plese S. Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis. Clin Neurol Neurosurg 2010, 112:641-645. 10.1016/j.clineuro.2010.04.020, 20570038.
12. van der Voort LF, Vennegoor A, Visser A, Knol DL, Uitdehaag BMJ, Barkhof F, Oudejans CBM, Polman CH, Killestein J. Spontaneous MxA mRNA level predicts Relapses in patients with recently diagnosed MS. Neurology 2010, 75:1228-1233. 10.1212/WNL.0b013e3181f6c556, 20921509.